App Amyloid Pathway In Alzheimer'S Disease represents a key pathological mechanism in neurodegenerative diseases. This page explores the molecular and cellular processes involved, their contribution to disease progression, and therapeutic implications.
The amyloid precursor protein (APP) processing pathway is central to Alzheimer's disease (AD) pathogenesis. APP is a transmembrane glycoprotein that can be processed through two distinct pathways: the amyloidogenic pathway, which generates amyloid-beta (Aβ) peptides, and the non-amyloidogenic pathway, which precludes Aβ formation. The balance between these pathways determines Aβ burden in the brain, making APP processing a critical therapeutic target.
¶ Gene and Protein Structure
The APP gene (located on chromosome 21q21.3) encodes a type I transmembrane protein with a large extracellular domain, a transmembrane helix, and a short cytoplasmic tail. APP undergoes post-translational modifications including glycosylation, sulfation, and phosphorylation. The protein belongs to the APP family, which includes APLP1 and APLP2 in mammals.
In the healthy brain, APP participates in:
- Synaptic formation and plasticity
- Neuronal survival signaling
- Iron export via ferroportin interaction
- Cell adhesion and migration
- Protection against oxidative stress
flowchart TD
A[APP in membrane] --> B{Processing Pathway}
B -->|Amyloidogenic| C[β-Secretase BACE1 cleavage] -->
B -->|Non-amyloidogenic| D[α-Secretase cleavage] -->
C --> E[sAPPβ fragment] -->
C --> F[C99 fragment] -->
D --> G[sAPPα fragment] -->
D --> H[CTFα fragment] -->
F --> I[γ-Secretase complex] -->
G --> J[Non-toxic fragments] -->
I --> K[Aβ peptides 1-40/1-42] -->
I --> L[AICD intracellular domain]
The β-site APP cleaving enzyme 1 (BACE1) initiates the amyloidogenic cascade by cleaving APP at the N-terminus of the Aβ domain, producing soluble APPβ (sAPPβ) and the membrane-bound C99 fragment. BACE1 expression is highest in neurons and is upregulated in AD brain.
The γ-secretase complex (comprising presenilin 1 or 2, NCT, APH-1, and PEN-2) cleaves C99 within the transmembrane domain to release Aβ peptides. The cleavage is imprecise, producing Aβ variants of varying lengths:
- Aβ1-40 (most abundant, ~80-90%)
- Aβ1-42 (more aggregation-prone, ~5-10%)
- Aβ1-43 (minor, highly aggregative)
α-Secretase cleavage (by ADAM10/ADAM17) occurs within the Aβ domain, precluding Aβ formation and producing the neuroprotective sAPPα fragment. This pathway is the predominant processing route in healthy neurons and can be upregulated by certain signaling pathways.
¶ Aβ Aggregation and Toxicity
Aβ peptides undergo conformational changes from random coil to β-sheet structures, leading to oligomerization, fibril formation, and plaque deposition. Aβ1-42 aggregates more rapidly due to two additional hydrophobic residues at the C-terminus.
- Synaptic dysfunction: Aβ oligomers bind to synapses, impairing long-term potentiation
- Oxidative stress: Aβ generates reactive oxygen species
- Calcium dysregulation: Membrane pores allow calcium influx
- Mitochondrial dysfunction: Aβ accumulates in mitochondria
- Neuroinflammation: Microglial activation by Aβ
| Mutation |
Effect |
Location |
| Swedish (K670N/M671L) |
Increased Aβ production |
β-secretase site |
| Arctic (E22G) |
Enhanced aggregation |
Aβ domain |
| Dutch (E22Q) |
Cerebral amyloid angiopathy |
Aβ domain |
| London (V717I) |
Increased Aβ1-42 |
γ-secretase site |
| Indiana (V717F) |
Increased Aβ1-42 |
γ-secretase site |
APP gene duplication causes early-onset AD with cerebral amyloid angiopathy, confirming Aβ dosage as sufficient for disease causation.
Multiple BACE1 inhibitors have been developed but faced challenges due to mechanism-based side effects. Notable candidates include:
- Verubecestat (MK-8931): Failed in Phase 3 trials
- Lanabecestat: Discontinued due to safety concerns
Rather than complete inhibition, modulators shift cleavage toward shorter, less aggregation-prone Aβ species.
- Aducanumab: Approved for early AD, removes plaques
- Lecanemab: Phase 3 CLARITY trial positive
- Donanemab: Phase 3 TRAILBLAZER-ALZ 2 positive
The study of App Amyloid Pathway In Alzheimer'S Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol Med. 2016;8(6):595-608.
- Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide. Nat Rev Mol Cell Biol. 2007;8(2):101-112.
- O'Brien RJ, Wong PC. Amyloid precursor protein processing and Alzheimer's disease. Annu Rev Neurosci. 2011;34:185-204.
- Vassar R. BACE1: the beta-secretase enzyme in Alzheimer's disease. J Mol Neurosci. 2004;23(1-2):105-114.
- De Strooper B, Vassar R, Golde T. The secretases: enzymes with therapeutic potential in Alzheimer disease. Nat Rev Neurol. 2010;6(2):99-107.
- Karran E, Mercken M, De Strooper B. The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov. 2011;10(9):698-712.
- Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297(5580):353-356.
- Sisodia SS, St George-Hyslop PH. gamma-Secretase, Notch, Abeta and Alzheimer's disease: implications of current therapeutic strategies. Nat Rev Neurosci. 2002;3(4):281-290.
- Citron M. Alzheimer's disease: strategies for disease modification. Nat Rev Drug Discov. 2010;9(5):387-398.
- Huang Y, Mucke L. Alzheimer mechanisms and therapeutic strategies. Cell. 2012;148(6):1204-1222.
- Querfurth HW, LaFerla FM. Alzheimer's disease. N Engl J Med. 2010;362(4):329-344.
- Ballard C, Gauthier S, Corbett A, et al. Alzheimer's disease. Lancet. 2011;377(9770):1019-1031.
- Masters CL, Bateman R, Blennow K, et al. Alzheimer's disease. Nat Rev Dis Primers. 2015;1:15056.
- Scheltens P, Blennow K, Breteler MM, et al. Alzheimer's disease. Lancet. 2016;388(10043):505-517.
- Hampel H, Hardy J, Blennow K, et al. The amyloid-β pathway in Alzheimer's disease. Mol Psychiatry. 2021;26(10):5481-5503.
- Xia X, Wang Q, Wang Y, et al. APP processing in Alzheimer's disease. Mol Brain. 2021;14(1):47.
- van der Kant R, Goldstein LS, Ossenkoppele R. Amyloid-beta-independent regulators of tau pathology in Alzheimer's disease. Nat Rev Neurol. 2020;16(1):22-34.
🟡 Moderate Confidence
| Dimension |
Score |
| Supporting Studies |
17 references |
| Replication |
0% |
| Effect Sizes |
25% |
| Contradicting Evidence |
0% |
| Mechanistic Completeness |
75% |
Overall Confidence: 47%